Adicet Bio (ACET) vs MiNK Therapeutics (INKT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
MiNK Therapeutics (INKT) has outperformed Adicet Bio (ACET) over the past year, losing 24.6% versus a loss of 61.4%. Over five years, INKT leads with a -90.8% price change compared with -95.5% for ACET. MiNK Therapeutics is the larger company by market cap ($56.1 million vs $53.7 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACET | INKT |
|---|---|---|
| Share price | $5.74 | $11.00 |
| Market cap | $53.73M | $56.13M |
| 1-day change | -7.12% | -3.68% |
| YTD return | -31.83% | -1.35% |
| 1-year return | -61.38% | -24.61% |
| 5-year return | -95.54% | -90.83% |
| EPS (TTM) | $-10.42 | $-2.39 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $17.44 | $16.93 |
| 52-week low | $5.55 | $8.48 |
| Distance from 52-week high | -67.09% | -35.02% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +506.79% | +254.55% |
| Average volume | 172.38K | 13.80K |
| Shares outstanding | 9.36M | 5.10M |
| Employees | 102 | 15 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- INKT has outperformed ACET by 36.8 percentage points over the past year.
About Adicet Bio
ACET stock →Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company's lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases.
Healthcare · Biotechnology · 102 employees
About MiNK Therapeutics
INKT stock →MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of allogeneic, off-the-shelf, and invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company develops agenT-797, an off-the-shelf, allogeneic, and native iNKT cell therapy that is in Phase 2 clinical trial for the clinical safety and efficacy of the combination of agenT-797, botensilimab and balstilimab with ramucirumab and paclitaxel for patients with previously treated, advanced esophageal, gastric, or gastroesophageal junction adenocarcinoma; Phase 1 trial as a monotherapy in combination with anti-PD-1 checkpoint inhibitors, pembrolizumab, and nivolumab for refractory solid tumor cancers; and Phase 1 trial for the treatment of moderate to severe viral acute respiratory distress syndrome (ARDS).
Healthcare · Biotechnology · 15 employees
ACET vs INKT FAQ
Which is bigger, Adicet Bio or MiNK Therapeutics?
MiNK Therapeutics (INKT) is larger, with a market capitalization of $56.13M compared with $53.73M for Adicet Bio (ACET).
Which stock has performed better over the past year, ACET or INKT?
INKT returned -24.61% over the past 12 months, compared with -61.38% for ACET (price return, excluding dividends). Past performance does not predict future results.
Are Adicet Bio and MiNK Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.